Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C, ORARIALS-01 trial team

Open source

DOI: 10.1016/s1474-4422(24)00134-0
Published: 2024 Jul
Container: The Lancet. Neurology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-24-00134-0,
  title = {Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.},
  author = {Benatar M and Hansen T and Rom D and Geist MA and Blaettler T and Camu W and Kuzma-Kozakiewicz M and van den Berg LH and Morales RJ and Chio A and Andersen PM and Pradat PF and Lange D and Van Damme P and Mora G and Grudniak M and Elliott M and Petri S and Olney N and Ladha S and Goyal NA and Meyer T and Hanna MG and Quinn C and Genge A and Zinman L and Jabari D and Shoesmith C and Ludolph AC and Neuwirth C and Nations S and Shefner JM and Turner MR and Wuu J and Bennett R and Dang H and Sundgreen C and ORARIALS-01 trial team},
  year = {2024},
  journal = {The Lancet. Neurology},
  doi = {10.1016/s1474-4422(24)00134-0},
  url = {https://doi.org/10.1016/s1474-4422(24)00134-0}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
AU  - Benatar M
AU  - Hansen T
AU  - Rom D
AU  - Geist MA
AU  - Blaettler T
AU  - Camu W
AU  - Kuzma-Kozakiewicz M
AU  - van den Berg LH
AU  - Morales RJ
AU  - Chio A
AU  - Andersen PM
AU  - Pradat PF
AU  - Lange D
AU  - Van Damme P
AU  - Mora G
AU  - Grudniak M
AU  - Elliott M
AU  - Petri S
AU  - Olney N
AU  - Ladha S
AU  - Goyal NA
AU  - Meyer T
AU  - Hanna MG
AU  - Quinn C
AU  - Genge A
AU  - Zinman L
AU  - Jabari D
AU  - Shoesmith C
AU  - Ludolph AC
AU  - Neuwirth C
AU  - Nations S
AU  - Shefner JM
AU  - Turner MR
AU  - Wuu J
AU  - Bennett R
AU  - Dang H
AU  - Sundgreen C
AU  - ORARIALS-01 trial team
PY  - 2024
JO  - The Lancet. Neurology
DO  - 10.1016/s1474-4422(24)00134-0
UR  - https://doi.org/10.1016/s1474-4422(24)00134-0
ER  -

APA

M, B., T, H., D, R., MA, G., T, B., W, C., M, K., LH, V. D. B., RJ, M., A, C., PM, A., PF, P., D, L., P, V. D., G, M., M, G., M, E., S, P., N, O., S, L., NA, G., T, M., MG, H., C, Q., A, G., L, Z., D, J., C, S., AC, L., C, N., S, N., JM, S., MR, T., J, W., R, B., H, D., C, S., & team, O. T. (2024). Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(24)00134-0

Source records

pubmed · retrieved 2026-09-26T13:01:01.021Z